Last reviewed · How we verify
NCT04726241
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Phase 1, PHASE2 trial testing Biospecimen Collection in Acute Lymphoblastic Leukemia in 960 participants. Currently enrolling.
31 December 2030
Quick facts
| Lead sponsor | PedAL BCU, LLC |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 960 |
| Start date | 18 April 2022 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2030 |
| Sites | 182 locations across New Zealand, Canada, Puerto Rico, Australia, United States |
Drugs / interventions tested
- Biospecimen Collection — full drug profile →
Conditions studied
- Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- Acute Myeloid Leukemia Post Cytotoxic Therapy — all drugs for Acute Myeloid Leukemia Post Cytotoxic Therapy →
- Juvenile Myelomonocytic Leukemia — all drugs for Juvenile Myelomonocytic Leukemia →
Sponsor
PedAL BCU, LLC
Who can join
Under 22, any sex, with Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.
Cooper TM, Alonzo TA, Tasian SK, Kutny MA, et al · · 2023 · cited 22× · PMID 37480164 · DOI 10.1002/pbc.30584 -
Tumor Genomic Profiling and <i>Ex Vivo</i> Drug Sensitivity Testing for Pediatric Leukemia and Lymphoma Patients.
Eaton A, Wong V, Schiff D, Anderson E, et al · · 2022 · cited 5× · PMID 35241983 · DOI 10.5863/1551-6776-27.2.123 -
The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Ceolin V, Ishimaru S, Karol SE, Bautista F, et al · · 2023 · cited 3× · PMID 38201506 · DOI 10.3390/cancers16010078
Verify or expand the search:
- PubMed search for NCT04726241
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biospecimen Collection
Trials testing the same drug.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT05621291 — A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Follo · NA · recruiting
- NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
- NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04726241 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PedAL BCU, LLC
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04726241.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing